AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04143893 — intervention group
Intervention type: DRUG
Intervention: Optimal medical treatment
Description: Patients with cardiogenic shock who received optimal medical treatment including vasopressor
Study NCT02188771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-articular administration of RegenoGel-SP or hyaluronic acid (HA)
Description: Intra-articular Injection: single injection of RegenoGel SP or 3 injections of HA
Study NCT02808793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK002
Study NCT05303077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutribén Innova® 1
Description: Infants are fed solely with infant formula supplemented with an inactive probiotic and omega 3 fatty acids over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's
Study NCT05303077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutribén®
Description: Infants are fed solely with infant formula over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's age.
Study NCT01747577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate
Description: Oral
Study NCT01747577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT05303077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeed
Description: Infants are breastfeeding solely over the first 6 months of their life, from then on the infants are fed as recommended by their caregiver, as if they are not participating in a research study.
Study NCT06713629 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardiac surgery via median sternotomy
Description: For both groups, the same median sternotomy cardiac surgery procedure
Study NCT06713629 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac surgery via median sternotomy
Description: For both groups, the same median sternotomy cardiac surgery procedure
Study NCT02083614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: to clamp or release the catheter for 2 days before removal
Study NCT06713876 — intervention group
Intervention type: DEVICE
Intervention: VA-ECMO-assisted PCI
Description: A total of 220 consecutive patients with VA-ECMO-assisted PCI will be enrolled. Data related to medical history, procedural characteristics, and outcomes were collected. Clinical follow-up will be conducted in the periprocedural and postoperative at 1 month, 1 year, 2 years, 3 years, 4 years, and 5 years.
Study NCT01122433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation using the C-MAC video laryngoscope
Description: Using the C-MAC video laryngoscope for endotracheal intubation after failed direct laryngoscopy
Study NCT00338104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Insulin glargine given at 40% of prior stable drip rate.
Study NCT00338104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Insulin glargine given at 60% of prior stable drip rate.
Study NCT00338104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Insulin glargine given at 80% of prior stable drip rate.
Study NCT04017000 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bladder Shape Test
Description: Capturing images of bladder under natural filling conditions images are analysed at a later date for shape change.
Study NCT04017000 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Calibration images
Description: Capturing images of bladder under artificial filling conditions during Urodynamic assessment images are analysed at a later date to inform shape change technology.
Study NCT03685695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03685695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Wear Fitbit Charge 2
Study NCT03685695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Complete aimed walking steps
Study NCT03685695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03685695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01303783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (Atacand), 4 mg
Description: 4 mg of candesartan as capsule
Study NCT01303783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (Atacand), 8 mg
Description: 8 mg candesartan as capsule
Study NCT01303783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (Adalat, BAYA1040), 20 mg
Description: 20 mg nifedipine as tablet
Study NCT01772251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi Icp
Study NCT01045733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof IQ Toric IOL
Description: AcrySof IQ Toric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
Study NCT01045733 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AcrySof IQ Aspheric IOL
Description: AcrySof IQ aspheric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
Study NCT03649945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2，3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
Study NCT01045733 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limbal Relaxing Incision (LRI)
Description: An incision was made at the corneal-limbal junction during cataract surgery for the purpose of relaxing corneal curvature, ie., correcting astigmatism.
Study NCT03649945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nedaplatin
Description: 80 mg/m2,3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
Study NCT03649945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endostar
Description: 7.5mg/m2，once a day, continuously dosed for 14 days, then stop for 7 days,3 weeks for one cycle, totally 6 cycles
Study NCT03425643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
Study NCT03425643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline by IV infusion Q3W, given on cycle day 1.
Study NCT03425643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
Study NCT03425643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
Study NCT03425643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 by IV infusion Q3W, given on cycle days 1 and 8. Given only to participants with squamous NSCLC.
Study NCT03425643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m\^2 by IV infusion Q3W, given on cycle days 1 and 8. Given only to participants with squamous NSCLC.
Study NCT03425643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.
Study NCT03425643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.
Study NCT03354390 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell infusion
Description: This is a phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLA-A\*11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a dose limiting toxicity (DLT). Patients with evaluable advanced/metastatic ccRCC will be recruited in up to 4 dose levels.
Study NCT04377633 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Oral handover
Description: Anesthesia handover during surgery will be performed as usual, i.e., oral exchange of pertinent clinical information.
Study NCT01848717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINTLIFT®
Study NCT04377633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Checklist handover
Description: Anesthesia handover during surgery will be performed according to a structured handover checklist.
Study NCT04644016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine
Study NCT04644016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine
Study NCT04644016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan per PK
Study NCT04644016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine-A
Description: GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.
Study NCT04644016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.
Study NCT04644016 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord Blood Graft
Description: The CB graft will be infused on day 0 per standard practice
Study NCT03698136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation of denervated muscles
Description: The study investigates the effect of electrical stimulation on denervated muscles in the forearm and hand regarding muscle structure and thickness. The study will be performed on tetraplegics who have either paralysed the wrist extensor, the short thumb spreader or the muscle between the thumb and index finger.The study lasts 12 weeks and consists of an ultrasound examination at the beginning and end of the study and an intermediate stimulation phase.The stimulation takes place either during an inpatient stay or at home for 12 weeks, 5 times a week 33 minutes.
Study NCT04386408 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination of plant extracts (BSL_EP027)
Description: Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
Study NCT04386408 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
Study NCT02462434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early palliative care team consultation
Description: The palliative care team will evaluate the patient and family with the following core palliative care goals in mind: evaluating maternal understanding of their child's diagnosis and eliciting maternal concerns regarding their child's physical symptoms, identifying maternal social support systems and additional life stressors, identifying maternal expectations and hopes for their child's medical care, and assessing maternal fears surrounding their child's diagnosis and medical treatments. Palliative care team support and resources will then be provided in areas of necessity identified for the family. Palliative care team follow up will then be determined based on the level of need identified for each individual study participant.
Study NCT00006034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: keyhole limpet hemocyanin
Description: Given intradermally and IV
Study NCT00006034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT02960776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR)
Description: Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time. A delay in bedtimes was chosen rather than advancing wake-up time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
Study NCT00877994 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurture Support Group Therapy
Description: Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists.
Study NCT00877994 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group therapy
Description: Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists. The curriculum will focus on increasing positive healthy eating patterns in children of mothers who have had disordered eating and body image struggles.
Study NCT03361735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Intramuscular or subcutaneous injection
Study NCT03361735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Subcutaneous injection
Study NCT03361735 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT03361735 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 Dichloride
Description: Given IV
Study NCT03361735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03361735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Subcutaneous injection
Study NCT03337503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC and CDB in a 1 to 1 ratio
Description: capsule containing cannabis oil
Study NCT03337503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: THC and CBD in a 1 to 2 ratio
Description: capsule containing cannabis oil
Study NCT03337503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High CBD with trace THC oil
Description: capsule containing cannabis oil
Study NCT03337503 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: carrier oil capsule
Study NCT03869034 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HAIC+PD1
Description: Sintilimab ( 200mg Q3W iv D1)+FOLFOX-HAIC（oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3), maximally 8 cycles Multi-disciplinary consultation was organized to decide the chance of surgery and subsequent treatment per 2 treatment cycles. Patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection. After recovery from operation , sintilimab monotherapy was given per three weeks for maximally 16 doses. Patients who were ineligible for resection would continue to receive the combination therapy.
Study NCT03869034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC
Description: FOLFOX-HAIC: oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3, for maximally 8 cycles, and the safety parameters are reviewed before the start of each course of HAIC treatment. Patients who achieve partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and are assessed as eligible for R0 resection go on to undergo surgical resection. No other anti-tumor therapies are allowed before PD or postoperative relapse is confirmed.
Study NCT01109576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DSL Workshop
Description: A series of 6 weekly 2 hour interactive workshops for Veterans with age-related Dual Sensory Loss that provide instruction, skills training, exercises and facilitated interaction among peers.
Study NCT04381676 — intervention group
Intervention type: OTHER
Intervention: Flipped Classroom Approach
Description: In the Flipped Classroom, participants form groups of 2-3 and are instructed to work together through clinical cases of the in-class case based activity, committing to group answers to the clinical questions before advancing to the next case. At the end of class, the faculty instructor facilitated a short interactive group discussion.
Study NCT01188226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Denture teeth
Description: Denture teeth made of nano hybrid composite material
Study NCT04643743 — intervention group
Intervention type: DEVICE
Intervention: Endarterectomy
Description: Endarterectomy is a surgical procedure to remove the atheromatous plaque material, or blockage, in the lining of an artery constricted by the buildup of deposits. It is carried out by separating the plaque from the arterial wall.
Study NCT00323089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microcoil insertion and excision
Description: The objective of this study is to determine if subcentimetre pulmonary nodules can be accurately and safely excised by endoscopic stapling devices after they have been localized using CT and marked with a microcoil device.
Study NCT02583074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stimulation
Description: After surgery, patients in 'Neurostimulation Group' will receive subthalamic nucleus stimulation for 3 months.
Study NCT02583074 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-stimulation
Description: After surgery, patients in 'sham-stimulation Group' will receive subthalamic nucleus sham-stimulation for 3 months.
Study NCT01182870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: choleclaciferol
Description: 800-6000 IU cholecalciferol per day
Study NCT01182870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: choleclaciferol
Description: 800-6000 IU cholecalciferol per day
Study NCT01162655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for Insomnia (CBT)
Description: 6-week course of CBT delivered either using internet or telehealth
Study NCT03410667 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Phase One: Exploration
Description: Spina Bifida patients from the pediatric urology clinic at Riley Hospital and their caregivers will participate in discussions of UI goals. These patients will self report their experiences and perspectives using a Day in the Life diary tool-kit.
Study NCT03410667 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Phase Two: Creation
Description: Patients, caregivers and providers will work to create a goal setting tool to help patients and physicians appropriately address the issue of UI in patients with spina bifida.
Study NCT03410667 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Phase Three: Reflection
Description: This is a validation step to test whether the goal-setting tool is widely applicable and functional in a clinic setting. There will be cognitive interviews after the tool is completed to gather patient impressions.
Study NCT03410667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aim 3
Description: This will be a large scale validation of the app, with assignment to standard care for the first year of enrollment.
Study NCT03936062 — intervention group
Intervention type: DRUG
Intervention: Sitagliptin
Description: Sitagliptin dispensing claim is used as the exposure
Study NCT03936062 — intervention group
Intervention type: DRUG
Intervention: Sulfonylurea
Description: 2nd generation sulfonylurea dispensing claim is used as the reference
Study NCT00575978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Description: Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
Study NCT03618095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOTUS Edge Valve System
Description: TAVR with the LOTUS Edge Valve System
Study NCT03765567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 2 vials of Vancomycin 1g powder will be applied topically to the open fracture wound site.
Study NCT01303783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (Adalat, BAYA1040), 30 mg
Description: 30 mg nifedipine as tablet
Study NCT01303783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (Adalat, BAYA1040), 60 mg
Description: 60 mg nifedipine as tablet
Study NCT01303783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 different placebo tablets corresponding nifedipine doses and 1 placebo capsule corresponding to candesartan doses